Home / Health / Italian study found people infected with COVID-19, the death toll decreased after impact.

Italian study found people infected with COVID-19, the death toll decreased after impact.



Health workers supervising the vaccine Pfizer-BioNTech COVID-19 at the Coronavirus Vaccination Center (COVID-19) in Naples, Italy, January 8, 2021.REUTERS / Ciro De Luca

Covid-19 infection among adults of all ages was reduced by 80% in 5 weeks after receiving Pfizer (), Modernna (), Moderna () or AstraZeneca vaccines. (AZN.L) first according to Italian research published on Saturday.

The first such study by EU countries on the real-world impact of this immunization campaign was conducted by the Italian National Institutes of Health (ISS) and the Ministry of Health on vaccinated people. 13.7 million people nationwide

Scientists began to study the data from the date the Italian vaccination campaign began on December 27, 2020, until May 3, 2021.

The analysis showed that the risk of SARS-CoV-2 infection, hospitalization, and death continued to decline after the first two weeks after the first vaccination.

“By 35 days after the first dose, 80% of infections, 90% of hospitalizations and 95% of mortality,” ISS said, adding that the pattern. The same is found in both men and women, regardless of age.

“This information confirms the effectiveness of the vaccination campaign and the need for rapid population-wide coverage to end the emergency,” ISS Silvio Brusaferro said in a statement.

Among the nearly 14 million people included in the Italian study, 95% of those taking Pfizer and Moderna received a complete vaccine, while no people receiving AstraZeneca received a second dose.

So far, Italy has followed the manufacturer’s recommendations, giving Pfizer a second dose, three weeks after the first, Moderna a second after a four-week gap and AstraZeneca a second after a 12-week hiatus.

As of Saturday morning, 8.3 million Italians, or 14% of the population, were fully vaccinated, while about 10 million received their first vaccination.

Our Standard: The Thomson Reuters Trust Principle.


Source link